🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Twenty-two researchers from David Geffen School of Medicine at UCLA named to a list of the world’s most influential scholars in the sciences. Read more: ucla.in/3VbI2wO

The first report of circulating tumor cells in the literature. 150 years ago, in 1869, the case of Australian doctor Thomas Ashworth👇 collections.mdhs.unimelb.edu.au/objects/27718/…

Congrats to Aditya Bardia, MD on being named Editor-in-Chief of the peer-reviewed journal Breast Cancer Research and Treatment! Under Bardia’s leadership, the journal will cover various domains of breast cancer care, with an “author and reader” centric view. bit.ly/3D3ITtf

Day 1 of #SABCS24 is here! UCLA researchers share the latest in breast cancer care, including improved survival in advanced disease, using genomics to identify recurrence & understanding how race/ethnicity influences heart failure risk. Learn more: bit.ly/49wOm8o

Today at SABCS, we are proud to honor 5 exceptional leaders for their groundbreaking work in advancing our understanding of breast cancer risk, metastasis, personalized treatments & education. Read more: bit.ly/4fco6Ba #SABCS24

Congratulations Mina S. Sedrak for the well deserved honor Susan G. Komen! Dr. Sedrak UCLA Jonsson Comprehensive Cancer Center is leading cutting-edge translational research and clinical trials with significant implications for the field of cellular senescence and cancer therapeutics. #bcsm OncoAlert

I’m honored to moderate an important #SABCS2024 spotlight session on bridging the gap in racial disparities and advancing global health equity. Join us tomorrow at 7 AM for Poster Spotlight Session 10: Addressing Racial Disparities in Breast Cancer Outcomes. 📍 Location:

Wonderful team dinner UCLA Jonsson Comprehensive Cancer Center UCLA Health with Mina S. Sedrak Marla Lipsyc-Sharf, MD Aditya Bardia, MD #SABC24

ZEST: MRD guided tx n=1901 surveillance (88% TNBC), 147 (8% ctDNA+, highest w/i first 3 mo; 60% w/i 6mo) ctDNA+: 50% radiologic recurrence, subsequent test 43.8% recurrence 40 pts randomized: HR 0.66 High rates of metastatic dz if ctDNA+ SABCS #SABCS24 @oncolaert

Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review. First line CDK 2nd line profile driven ADC/chemo once endo-R! SABCS #SABCS24 OncoAlert

Congratulations VIRGINIA KAKLAMANI Carlos L. Arteaga, M.D. and team for another fantastic conference. 👏 Bringing people together to improve breast cancer outcomes. #bcsm Margaret Foti, PhD, MD (hc) #AACR

The GRASP Scientist for this session (Rachel Occhiogrosso Abelman, MD) trained under Dr. Bardia (Aditya Bardia, MD) & will discuss biomarkers for HR+ patients in the metastatic setting. #bcsm

‼️UCLA at SABCS 2024: Advancing Breast Cancer Research in Survival, Genomics, and Disparities UCLA's groundbreaking research presented at SABCS 2024 is advancing breast cancer care by addressing survival, genomics, and disparities, paving the way for improved treatment and

I am beyond excited and extremely honored to receive a ASCO Conquer Cancer, the ASCO Foundation Young Investigator Award! HUGE thank you to my amazing mentors! Heather McArthur, MD, MPH Sumanta K. Pal, MD, FASCO stephen shiao Aditya Bardia, MD City of Hope UCLA Jonsson Comprehensive Cancer Center

Hear Erika Hamilton, MD of Sarah Cannon Docs, Heather McArthur, MD, MPH, FASCO of UT Southwestern Medical Center, and Kelly McCann, MD, PhD of UCLA discuss sequencing for HER2+ metastatic breast cancer after progression on first-line therapy.. Watch more here: hubs.li/Q03n-vRJ0

Love that Conquer Cancer, the ASCO Foundation managed to capture in the video below this simply magical moment when Alexis LeVee, MD won her ASCO YIA! It has been a joy to co-mentor this superstar in #breastcancer w Heather McArthur, MD, MPH UTSW Simmons Cancer Center (Heather, TY! As a #kidneycancer doc I was way out of my

You're just in time! Let's take a sneak peek at the top #BreastCancer abstracts presented at #ASCO25 anticipated by experts in the space. @AlexisLeVee Paolo Tarantino Dr Sarah Sammons Sara Tolaney Sign up here: hubs.li/Q03pMhtZ0

📰 Dr. Arielle Medford led this genomic & proteomic profiling of GATA3mut in HR+ MBC -Distinct ctDNA-based genomic landscape -CPTAC analysis suggests mechanism for sensitivity to MDM2 inhibition -GATA3mut associated with poorer survival on ET monotherapy link.springer.com/article/10.100…

Take homes from #ASCO25 rechallenge with tdxd after ild can work; sg first line tnbc; vepdeg me too; inavo impressive in endocrine resistant; dose escalation of abema better; tdxd first line her2 but maybe try maintenance hp; ofs for high risk a must; nk3 for hot flashes #bcsm

Overview of ASCO 2025 Breast Cancer topics! #ASCO25 OncoAlert ASCO So many important topics.